Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

Home

/

SRRK

S

Scholar Rock Holding Corporation (SRRK)

NMS – Real vaqt narxi. Valyuta: USD

53.62

+1.55 (2.98%)

Bozor ochiq: Aug 12, 2026, 1:47 PM EDT

52.07

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its application seeking FDA approval for a rare neuromuscular disease drug.

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA review of the apitegromab Biologics License Application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) is progressing with the Company's second fill-finish facility. The B.

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock NASDAQ: SRRK said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the company prepares for a potential launch of the muscle-targeted treatment for spinal muscular atrophy, or SMA.

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent company developments. “We are on the threshold of securing the world's first ever regulatory approval of a myostatin inhibitor, whi.

Videolar

No Data

There is no data to display

Press-relizlar

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA review of the apitegromab Biologics License Application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) is progressing with the Company's second fill-finish facility. The B.

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent company developments. “We are on the threshold of securing the world's first ever regulatory approval of a myostatin inhibitor, whi.